| Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. | |
| | |
MedLine Citation:
|
PMID: 17522372 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The goal was to investigate the effect of micronized fenofibrate, a hypolipidemic drug, on inflammatory markers and proinsulin in patients with type 2 diabetes who had hyperlipidemia. Thirty-nine patients were treated with micronized fenofibrate (200 mg/day for 12 wk). Erythrocyte sedimentation rate (ESR), fibrinogen, high-sensitivity C-reactive protein (hs CRP), and proinsulin levels were measured at baseline and after 12 wk of therapy. Micronized fenofibrate significantly reduced serum triglyceride, cholesterol, and uric acid levels (all p <0.0001) and increased high-density lipoprotein (HDL)-cholesterol (p <0.001) and creatinine levels (p <0.0001). Micronized fenofibrate also significantly decreased fibrinogen (421 +/- 152 vs 344 +/- 81 mg/dl, p <0.001), hs-CRP (3.3 +/- 3.3 vs 2.1 +/- 1.8 mg/L, p <0.01), and ESR (19.1 +/- 24.8 vs 9.7 +/- 8.7 mm/hr, p <0.01), but did not change proinsulin levels. The correlations among changes of hs-CRP, fibrinogen, and ESR were high. Although correlation among the decreases in inflammatory markers (ESR, fibrinogen, and hs-CRP) was significant, there was no significant correlation between the changes of lipid profile and inflammatory markers. In conclusion, after 12 wk, micronized fenofibrate therapy significantly decreased 3 inflammatory markers (hs-CRP, ESR, and fibrinogen) and improved the lipid profile by decreasing serum triglyceride, cholesterol, and non-HDL-cholesterol levels and increasing HDL-cholesterol; however, it did not change serum proinsulin level, a pancreatic stress marker. |
| | |
Authors:
|
Ta-Jen Wu; Horng-Yih Ou; Chien-Wen Chou; Shu-Hwa Hsiao; Chia-Yin Lin; Pai C Kao |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Annals of clinical and laboratory science Volume: 37 ISSN: 0091-7370 ISO Abbreviation: Ann. Clin. Lab. Sci. Publication Date: 2007 |
Date Detail:
|
Created Date: 2007-05-24 Completed Date: 2007-06-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0410247 Medline TA: Ann Clin Lab Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 158-66 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use* Atherosclerosis / metabolism* Biological Markers / blood* Blood Sedimentation C-Reactive Protein / metabolism* Cholesterol / blood Diabetes Mellitus, Type 2 / blood, drug therapy* Fibrinogen / metabolism Humans Hyperlipidemias / blood, drug therapy* Outpatients Procetofen / therapeutic use* Proinsulin / blood Risk Factors Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Biological Markers; 0/Triglycerides; 49562-28-9/Procetofen; 57-88-5/Cholesterol; 9001-32-5/Fibrinogen; 9007-41-4/C-Reactive Protein; 9035-68-1/Proinsulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Simple immunohistochemical staining method using large sized gold colloid conjugated secondary antib...
Next Document: Eluate testing following microscopically positive direct antiglobulin tests with anti-IgG.